A potent, selective, reversible inhibitor of PTP SHP2 with IC50 of 5.5 uM, exhibits >3-fold selectivity for SHP2 over other PTPs.

A potent, selective, reversible rhomboid proteases inhibitor with Ki of 45 nM for GlpG .

A potent, selective, reversible, ATP-competitive Chk2 inhibitor with IC50 of 0.2 uM.

A potent, selective. covalent protein lysine methyltransferase SETD8 inhibitor with IC50 of 804 nM.

A potent, selectove δ-opioid receptor agonist with Ki of 0.16 nM, dispalys 133.5-fold and 960.5-fold selectivity over μOR and κOR respectively.

A potent, small molecule fetal hemoglobin (HbF) inducer with EC50 of 100 nM.

A potent, small molecule inhibitor of the proteasome subunit Rpn11 with IC50 of 2.5 uM..

A potent, specfic casein kinase 1δ (CK1δ) inhibitor with IC50 of 40 nM.

A potent, specfic CXCR2 antagonist that inhibits IL8 down-regulation of forskolin-induced cAMP with IC50 of 7.79 uM.

A potent, specific acyl protein thioesterase 2 (APT-2, LYPLA2) inhibitor with IC50 of 144 nM and Ki of 120 nM, >20-fold selectivity over APT-1 and serine hydrolase enzyme family.

A potent, specific and allosteric mGluR1 antagonist with IC50 of 6 nM and 1.4 nM for human and mouse mGluR1, respectively..

A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM.

A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM.

A potent, specific and nonlipid agonist of LPA2 receptor with EC50 of 3.3 uM, does not activate any of the other LPA GPCRs (>10 uM).

A potent, specific and orally active 5-Lipoxygenase-activating protein (FLAP) inhibitor with IC50 of 1.6 nM in FLAP binding assay.

A potent, specific and orally bioavailable soluble epoxide hydrolase (sEH) inhibitor with IC50 of 1.3 nM.

A potent, specific BMP receptor activin receptor-like kinase 3 (ALK3) antaognist with Ki of 5.4 nM.

VU 0465350 is a potent, specific BMP receptor activin receptor-like kinase 3 (ALK3) antaognist with Ki of 92.3 nM; shows no activity for ALK2/4/5, also shows affinity for TGFBR2, VEGFR2 and AMPK; blocks SMAD phosphorylation in vitro and in vivo, and enhances liver regeneration after partial hepatectomy.

A potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively.

A potent, specific cell-active VHL E3 ubiquitin ligase inhibitor that inhibits VHL/HIF-α interaction with Kd of 90 nM in ITC assays.

A potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively.

A potent, specific immunoproteasome LMP7 subunit inhibitor with IC50 of 25 nM, >100-fold selectivity over β5c, β1i, β1c, β2i and β2c subunits (IC50>3 uM).

A potent, specific immunoproteasome β1i (LMP2) subunit inhibitor with IC50 of 104 nM, 144- and 10-fold selectivity over β1c and β5 subunit respectivey.

A potent, specific immunoproteasome β5 subunit inhibitor with IC50 of 17 nM, 21-fold and 13-fold selectivity for β5 over LMP7 and LMP2 subunits, respecitvely..

A potent, specific immunoproteasome β5 subunit inhibitor with IC50 of 44 nM, 105 and 225-fold selectivity over β2i and β1i subunit, respecitvely.

A potent, specific immunoproteasome β5 subunit inhibitor..

A potent, specific inhibitor of HCV NS5B polymerase and HCV replication (IC50=1.28 uM, replicon assay).

A potent, specific inhibitor of the SGK1 kinase activity, induces autophagy, apoptosis and ER stress in cancer cells.

MMV019313 (MMV 019313, MMV-019313) is a potent, specific malaria bifunctional farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) inhibitor with IC50 of 330 nM; shows no activity against human FPPS or GGPPS (>200 uM); exhibits distinct modes of inhibition compared with bisphosphonates, inhibits P. falciparum growth with EC50 of 268 nM, overexpression and an S228T variant of PfFPPS/GGPPS confer resistance to MMV 019313.

A potent, specific mechanism-based human NAD(P)H: quinone oxidoreductase 1 (NQO1) inhibitor that demonstrates efficient inactivation of NQO1 at 100 nM in in cellular systems.

A potent, specific P-gp inhibitor with Kd of 5.1 nM.

A potent, specific proteasome β5 subunit inhibitor with IC50 of 0.26 uM, 7.3 and 17.3-fold selectivity over β2i and β1i subunit, respecitvely..

A potent, specific RARα agonist with Ki of 2 nM, displays no significant effects on RARγ in reporter based assays..

A potent, specific S1P2 receptor (Edg-5) antagonist with IC50 of 3 nM, with no agonistic or antagonistic activities on other S1PRs.

A potent, specific survivin inhibitor that inhibits survivin promoter activity with IC50 of 0.54 nM.

A potent, specific, allosteric and cell-active inhibitor of KSP with IC50 of 11 nM.

A potent, specific, allosteric inhibitor of KSP motor domain ATPase with Ki of 12 nM.

A potent, specific, cell-active NADPH oxidase1 (Nox1) inhibitor that strongly blocks ROS generation in HT29 cells with IC50 of 0.129 uM.

A potent, specific, competitive inhibitor of choline kinase-α (Chok-α) by targeting the choline binding site; significantly increases LC3II expression in MCF-7 and MCF-7/TAM cells, increases the size and number of autophagosome, causes MCF-7 and MCF-7/TAM

A potent, specific, irreversible NIMA-related Kinase 2 (NEK2) inhibitor with IC50 of 16.65 nM.

A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively.

A potent, specific, orally active melanin concentrating hormone receptor 1 (MCHR1) inhibitor with kI of 3.8 nM, >100-fold selectivity over a battery of GPCRs, ion channels and enzymes.

A potent, specific, orally active pan-PKD (protein kinase D) inhibitor with biochemical IC50 of 1, 2.5 and 2 nM for PKD1, 2, and 3 respectively.

A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.

A potent, specific, orally bioactive small-molecule inhibitor of ubiquitin-conjugating enzyme UbcH5c with Kd of 283 nM.

A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM.

Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity. At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Pasireotide acetate) usually boasts enhanced water solubility and stability.

A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (pKi=8.2/9.0/9.1/<7.0/9.9 for sst1/2/3/4/5, respectively).

A potent, state-dependent blocker of Cav2 channels that preferentially inhibits potassium-triggered calcium influx through recombinant Cav2.2 under depolarized conditions with IC50 of 0.27 uM, compared with hyperpolarized conditions (IC50>20 uM).

A potent, subtype-selective Grp94 inhibitor with Kd of 0.96 uM, 13-fold selectivity over Hsp90α.

A potent, subtype-selective mGluR5 negative allosteric modulator with Ki of 6.1 nM.

NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding Ki values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively.

A potent, subtype-selective, orally available eIF4A3 inhibitor with IC50 of 0.14 uM.

A potential antipsychotic agent that binds selectively to D4 and 5-HT2A receptors with Ki of 3.0 and 5.8 nM, respectively.

A PP1 analog that has greater selectivity and potency for Zap-70(AS) over wild-type Zap-70, as assessed by Erk and Lat phosphorylation, as well as by proliferative responses of mature CD4+ cells.

A proton pump inhibitor that inhibits gastric acid secretion.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

IPAG is a prototypic selective inhibitor of sigma1 receptor that engages the unfolded protein response and induces autophagy in cancer cells.

A PSMA (prostate-​specific membrane antigen) ligand-​tubulysin compound..

A pungent agent isolated from Zingiber officinale Roscoe, has been known to have anti-tumor and anti-inflammatory effects.

A purine scaffold casein kinase 1δ/1ε (CK1δ/ε) inhibitor with IC50 of 160/540 nM, respectively..

A pyrimidine analog reverse transcriptase inhibitor (NRTI) for the treatment of HIV/AIDS.

A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine.

A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM.

A radioligand candidate for arginine vasopressin 1B (V1B) receptor that exhibits high binding affinities for human and rat V1B receptors with IC50 of 0.526 and 0.641 nM, respectively.

A RARβ/γ agonist originated from TTNPB, is also a selective inhibitor of aldo-keto reductase family member 1B10 (AKR1B10) with IC50 of 6.1 uM.

A RARβ-selective agonist that exhibits a full transcriptional agonistic activity and activating RARβ as efficiently as the reference agonist TTNPB.

A receptor adenine derivative binding membrane brain animal cell line.For the detailed information of 9-methyladenine, the solubility of 9-methyladenine in water, the solubility of 9-methyladenine in DMSO, the solubility of 9-methyladenine in PBS buffer, the animal experiment (test) of 9-methyladenine, the cell expriment (test) of 9-methyladenine, the in vivo, in vitro and clinical trial test of 9-methyladenine, the EC50, IC50,and Affinity of 9-methyladenine, Please contact DC Chemicals..

A resorcylic lactone type covalent kinase inhibitor that inhibits ALK1 with IC50 of 125 nM, also inhibits FLT3, VEGFR2, VEGFR3, MEK2 with IC50 of 1-10 nM..

A retinoic acid analog and selective RARα agonist

A reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.

A rodenticide that poisons the central nervous system by uncoupling mitochondrial oxidative phosphorylation, which causes a decrease in adenosine triphosphate (ATP) synthesis..

A ruthenium complex anticancer agent that is useful for metastatic tumors and cis-platin resistant tumors.

A second generation, orally biovailable pan-genotypic HCV NS5B polymerase inhibitor with EC50 of 1-10 nM.

A second-generation antihistamine that acts as a selective H1 receptor antagonist.

A second-generation SINE, orally bioavailable Exportin 1 (XPO1,CRM1) inhibitor with markedly reduced brain penetration compared to selinexor (30-fold less).

A selctive small molecule inhibitor of the transcription factor GATA-binding protein 2 (GATA2).

K-7174 dihydrochloride is a selctive small molecule inhibitor of the transcription factor GATA-binding protein 2 (GATA2).

A selecitve small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 8.9 uM.

Capadenoson is a selective agonist of adenosine-A1 receptor.

MG624 is a potent and selective neuronal α7 nAChR antagonist with a Ki of 106 nM.

A selective GPR68 positive allosteric modulator (pEC50=6.83) with minimal PAM activity at the related proton-sensing GPCRs GPR4 and GPR65.

A selective inhibitor of 26S proteasome subunit Rpn11 with IC50 of 10±2 uM.

A selective inhibitor of the gelatinases MMP2 and MMP9 and MMP13 with Ki of 85, 150 and 120 nM, respectively.

A selective monoamine oxidase B (MAO-B) inhibitor with IC50 of 1.4 uM, with less potency for MT-1 and MT-2.

A selective neuronal potassium channel (KCNQ/KV7 channel) activator that also has indirect NMDA receptor antagonist and GABAA receptor modulatory properties.

SR-11237 is a selective pan retinoid X receptor (RXR) agonist with no retinoid A receptor (RAR) activity. .

A selective prostaglandin E receptor subtype 4 (EP4) antagonist with pKi of 8.5.

A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.

A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.

A selective renal outer medullary potassium channel (ROMK, Kir1.1) inhibitor with IC50 of 8 uM in T1+ flux assays, does not inhibit Kir7.1 at 100 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 11.7 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 7.0 uM.

A selective small-molecule inhibitor of tisoprenylcysteine carboxyl methyltransferase (Icmt) with IC50 <200 nM, does not inhibit other enzymes (farensyltransferase, geranylgeranyltransferase type I, and Rce1) at concentrations up to 50 uM.

A selective TLR8 agonist that induces activation of NF-κB at 0.4 uM.

A selective TRPM8 channel blocker with pEC50 of 6.91 in Ca(2+) influx assay, with no activity for TRPV4 (pEC50<4.6).

A selective α2A receptor agonist that can reduce peripheral sympathetic outflow and thus cansues a reduction in peripheral sympathetic tone.

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension..

A selective Δ6 desaturase inhibitor that displays selectivity over Δ5 and Δ9 desaturases

A selective, competitive inhibitor of HMG-CoA reductase, that is also antilipemic.

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, non-competitive inhibitor of the kinetoplastid proteasome, inhibits the chymotrypsin-like activity of the T. cruzi proteasome with IC50 of 35 nM.

A selective, nonpeptidic, noncompetitive BACE1 inhibitor with IC50 of 3.15 uM in cell-free assays.

A selective, orally active JAK3 inhibitor that reduces IL-2-mediated JAK3 tyrosine phosphorylation with cellular IC50 of 10-20 uM.

A selective, orally bioactive and brain permeable δ-secretase (AEP.

A selective, potent peptidyl blocker of the big conductance Ca2+-activated K+ channel (BKCa, KCa1.1, MaxiK) with IC50 of 0.25 nM.

A selective, potent peptidyl blocker of the big conductance Ca2+-activated K+ channel (BKCa, KCa1.1, MaxiK).

A selective, reversible inhibitor of MAO-A and serotonin reuptake inhibitor as an antidepressant..

A selective, reversible inhibitor of MAO-A and serotonin reuptake inhibitor as an antidepressant..

A selective, reversible, high-affinity PAI-1 inhibitor that prevents PAI-1 from inactivating tPA and uPA with similar potency (IC50=30 and 25 nM, respectively).

A selective, small molecule inhibitor of PIP5K1C with IC50 of 41 nM, does not ihibits other lipid kinases including PI3Ks.

A selective, water-soluble, in vivo long-lasting AMPA antagonist with Ki of 43 nM.

A sepecific, orally bioavailable SHIP1 activator with no effect on functional androgen, oestrogen, oestrogen-related receptor α, glucocorticoid, mineralocorticoid and progesterone receptor at 30 uM.

A serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A simple DBCO-containing building block used to derivatize carboxyl groups in the presence of activators (e.g. EDC, or DCC) or activated esters (e.g. NHS esters) with DBCO moiety through a stable amide bond.

A small cardiogenic molecule that potently induces Nkx2.5 and a subset of other cardiac markers, including myocardin, troponin-I, and sarcomeric α-tropomyosin (SαTM) in a variety of different stem/progenitor cells.

A small cardiogenic molecule that potently induces Nkx2.5 and a subset of other cardiac markers, including myocardin, troponin-I, and sarcomeric α-tropomyosin (SαTM) in a variety of different stem/progenitor cells.

A small molecule 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, also possess affinity for the α1A- and α1B-adrenergic receptors..

A small molecule activator of S. aureus HssRS (heme sensor system) that induces endogenous heme biosynthesis by perturbing central metabolism.

A small molecule allosteric inhibitor of TREK channels with IC50 of 3.8, 1.7 and 10.3 uM for TREK-1, TREK-2 and TRAAK, respectively..

A small molecule allosteric inhibitor of TREK channels with IC50 of 5.0, 5.0 and 11.8 uM for TREK-1, TREK-2 and TRAAK, respectively..

A small molecule allosteric inhibitor of TREK channels with IC50 of 6.5, 4.4 and 15.7 uM for TREK-1, TREK-2 and TRAAK, respectively..

A small molecule anaphase-promoting complex/cyclosome (APC/C) inhibitor that binds to the APC preferentially suppresses APC/C(Cdc20) rather than APC/C(Cdh1).

A small molecule ANXA7 GTPase activity inhibitor, induces mouse ESCs differentiation to VECs.

A small molecule autophagy enhancer that induces autophagy independently of rapamycin in mammalian cells and enhances the clearance of autophagy substrates such as mutant huntingtin and A53T alpha-synuclein.

A small molecule autophagy enhancer that specificly inhibits myotubularin-related phosphatase MTMR14.

A small molecule BDNF mimetic that act as a direct and specific partial agonist of TrkB (EC50=200-500 pM), but not p75.

A small molecule binds to the EXO70 (exocyst component of 70 kDa) subunit of the exocyst complex (Kd=253 uM), resulting in inhibition of exocytosis and endosomal recycling in both plant and human cells and enhancement of plant vacuolar trafficking..

A small molecule CD4-mimetic that binds gp120 and blocks CD4 binding, inhibits HIV-1 entry with IC50 of 86.9 uM..

A small molecule CMKLR1 antagonist that inhibits chemerin-stimulated β-arrestin2 association with CMKLR1 (EC50=9.7 nM).

A small molecule cognitive enhancer that potentiates acetylcholine-mediated facilitation of inhibitory synaptic transmission in the hippocampal neurons.

A small molecule compound of prostaglandin D2（PGD2) inhibitor.

A small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM..

A small molecule Cu complexing ligand used for atom transfer radical polymerization (ATRP).

A small molecule Grb2 SH2 domain binding antagonist that synergistically enhances inhibition of K562 leukemia cell proliferation by imatinib (CI=0.774).

A small molecule inhibitor (IC50=0.3 uM) of DEAD-box polypeptide 3 (DDX3), a human host factor required for the replication of several DNA and RNA viruses.

A small molecule inhibitor of clathrin terminal domain and inhibits clathrin-mediated endocytosis.

A small molecule inhibitor of diacylglycerol kinase (DGK) with IC50 of 0.01-10 uM in isolated platelet membranes and in intact platelets.

A small molecule inhibitor of diacylglycerol kinase (DGK) with IC50 of 2.8 uM, inhibits the phosphorylation of OAG to OAPA with IC50 of 3.8 uM in intact platelets.

A small molecule inhibitor of Ezrin with Kd of 5.85 uM.

A small molecule inhibitor of guanine nucleotide exchange factor (GEF) catalytic activity that binds to SOS1 (Kd=14.7 uM) and disrupts GEF-Ras interaction.

A small molecule inhibitor of guanine nucleotide exchange factor (GEF) catalytic activity that binds to SOS1 (Kd=3.4 uM) and disrupts GEF-Ras interaction.

A small molecule inhibitor of HDM2-p53 interaction with FP IC50 of 0.7 uM.

A small molecule inhibitor of HECT-type ubiquitin ligase with IC50 of 6.8/6.3/6.9 uM for Smurf2/Nedd4/WWP1, respectively.

A small molecule inhibitor of HIV-1 entry via the CCR5 coreceptor.

A small molecule inhibitor of MDM2-p53 protein-protein interaction with IC50 of 16 uM..

A small molecule inhibitor of MDM2-p53 protein-protein interaction with IC50 of 5.3 uM in ELISA assay.

A small molecule inhibitor of NEMO (IKKγ)-ubiquitin binding with EC50 of 9.3 uM, directly binds to NEMO with Kd of 2.14 uM.

A small molecule inhibitor of polyglutamine (polyQ) aggregation in Huntington's disease neurons.

A small molecule inhibitor of PP2C that activates extensive 3' cleavage at a concentration 50-fold below that required by fluoride or CP..

A small molecule inhibitor of PSD-95/nNOS interaction with IC50 of 31 uM, without inhibiting nNOS catalytic activity.

A small molecule inhibitor of RAD51-mediated homologous recombination.

A small molecule inhibitor of RNA binding protein Lin28 that blocks the Lin28/let-7 interaction, rescues let-7 processing and function in Lin28-expressing cancer cells.

A small molecule inhibitor of RNA-binding protein Hu protein R (HuR) that interferes the HuR homodimerization with Kd of 7 nM.

A small molecule inhibitor of RNA-binding protein Hu protein R (HuR) that interferes the HuR homodimerization with Kd of 90 nM.

A small molecule inhibitor of Staphylococcus aureus sortase with IC50 of 9.3 uM.

A small molecule inhibitor of the NF-κB family member c-Rel with IC50 of 3 uM in EMSA assays.

A small molecule inhibitor of trans-translation that has broad-spectrum antibiotic activity.

A small molecule inhibitor of α4 integrin-dependent cell migration (IC50=0.5 uM, on the motility of Jurkat T cells) that functions by interacting with γ-parvin.

Filastatin is a long-lasting inhibitor of Candida albicans filamentation. Filastatin inhibits adhesion by multiple pathogenic Candida species with an IC50 of ~3 μM in the GFP-based adhesion assay. Filastatin inhibits fungal adhesion to polystyrene and human cells, the yeast-to-hyphal morphological transition, induction of the hyphal-specific HWP1 promoter. Filastatin has potent antifungal effect.

Navoximod (GDC-0919; NLG-​919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.

A small molecule iron transport inhibitor that promotes degradation of transferrin receptor-1 in vitro and in vivo, through a nystatin-sensitive lipid raft pathway.

A small molecule ligand for the methyl-lysine binding protein 53BP1 (p53-binding protein 1) with Kd of 22 uM against the 53BP1 tandem tudor domain.

A small molecule mitochondrial protein import blocker that inhibits Erv1 oxidase activity.

A small molecule NADH oxidase ENOX1 inhibitor with IC50 of 10 uM.

A small molecule positive allosteric modulator of both proton and vanilloid activation of TRPV1 (EC50=21.3 uM).

PDI inhibitor 16F16 is a protein disulfide isomerase (PDI) inhibitor, first identified in a screen for compounds that prevent apoptosis induced by mutant huntingtin protein. 16F16 not only suppressed apoptosis induced by the misfolded protein mutant hungtingtin, it also protected rat neurons from cell death triggered by Aβ peptide. The actions of this inhibitor helped to identify a new mechanism in which a cell death pathway is regulated by protein misfolding via PDI upregulation.

A small molecule ROS inducer that induces rapid cell death in cancer cells, induces reactive oxygen species via cellular glutathione depletion.

A small molecule sigma receptor ligand with Ki of 96 and 70 nM for sigma 1 and sigma 2, respectively.

A small molecule Skp2 E3 ligase inhibitor that prevents Skp2-Skp1 interaction and Skp2 SCF E3 ligase activity in vitro.

A small molecule TAAR1 agonist and β adrenoreceptor agonist that stimulates β1 and β2 adrenergic receptors.

A small molecule that disrupt 14-3-3 dimers at low micromolar concentrations and induce rapid down-regulation of Raf-MAPK and PI3K-Akt signaling in Jurkat cells.

A small molecule that inhibits NFATc1 and NF-κB activity, inhibits RANKL-induced osteoclastogenesis in vivo.

A small molecule that inhibits N-myristoyltransferase (NMT1) with IC50 of 8.7 uM, 10-fold enhanced inhibitory potency than LCL4.

A small molecule that inhibits the activities of E. coli DNA polymerase I and calf thymus DNA polymerase alpha..

NSC243928(NSC-243928 ) is a small molecule that potently inhibit ovarian cancer stem-like cells (CSC) growth with GI50 of 0.83 uM, which os consistent with cell death/apoptosis..

A small molecule that promotes differentiation of iPS-derived hepatocytes.

A small molecule that rapidly downregulates abscisic acid (ABA)-dependent gene expression (IC50=3 and 1.5 uM for RD29B and RAB18 promoters), also inhibits ABA-induced stomatal closure.

A small molecule that specifically inhibits the clathrin adaptor complex AP-1-dependent traffic, does not significantly affect other pathways through the trans-Golgi network (TGN).

A small molecule with activity against drug-resistant and persistent tuberculosis.

A small molecule, direct STAT3 inhibitor that inhibits the IL-6-induced SEAP expression with IC50 of 200-500 nM, blocks the binding of the activated STAT3 dimers to DNA.

A small molecule, full antagonist of CD4 that blocks gp120-CD4 interaction.

A small molecule, selective FOXO1 inhibitor that inhibits FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

A small molecule, specific Measles virus (MeV) entry inhibitor with IC50 of 55 uM.

A small-molecule compound that disrupts the Golgi apparatus by inhibiting the activation of ADP-ribosylation factor 1 (ARF1).

A small-molecule inhibitor of bacterial ribosome rescue that exhibits broad-spectrum antimicrobial activity against bacteria grown in liquid culture.

A small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 2 uM.

A small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 4 uM.

A small-molecule inhibitor of STAT3.

OB-1 is a small-molecule inhibitor of STOML3 oligomerization that reverses pathological mechanical hypersensitivity in vivo; effectively inhibits the self-association of stomatin, STOML1 and STOML2 at 2 uM, but not podocin; reversibly reduces the sensitiv

A small-molecule inhibitor of the interaction of the C. glabrata Pdr1 activation domain with the C. glabrata Gal11A KIX domain with Ki of 18 uM.

A small-molecule inhibitor of type III secretion in Y. pseudotuberculosis, without affecting in vitro multiplication, causes a dose- and growth phase-dependent inhibition of C. trachomatis RB multiplication..

A small-molecule inhibitor that blocks the Aurora C/IκBα interaction (IC50=24.9 uM) and exerts antitumor activity in MDA-MB-231 breast cancer cells.